Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse.

You must read this new presentation from Porter Stansberry.

Pierre Gravier Biography and Net Worth

CFO of PTC Therapeutics

Pierre Gravier brings more than 17 years of experience as an investment banker, venture capitalist and scientist to PTC.

Prior to joining PTC, Pierre was a managing director in the healthcare group of Perella Weinberg Partners, a leading independent global advisory firm. At Perella Weinberg, he focused on advising companies in the biopharmaceutical and pharmaceutical sectors on finance strategy and corporate development.

Prior to joining Perella Weinberg, Pierre worked as a healthcare investment banker at Barclays Capital. Previously, he was a Venture Capital Analyst at Société Générale Asset Management in Paris, where he focused on early-stage investments in the biotechnology sector. Pierre began his career as a Scientist at Ferring Pharmaceuticals.

Pierre holds a master’s degree in finance from ESCP Business School and a Master of Science in bioengineering from the University of Technology of Compiègne.

What is Pierre Gravier's net worth?: The estimated net worth of Pierre Gravier is at least $2.79 million as of July 16th, 2024. Mr. Gravier owns 53,531 shares of PTC Therapeutics stock worth more than $2,787,359 as of December 3rd. This net worth evaluation does not reflect any other investments that Mr. Gravier may own. Learn More about Pierre Gravier's net worth.
How old is Pierre Gravier?: Mr. Gravier is currently 38 years old. There are 7 older executives and no younger executives at PTC Therapeutics. The oldest executive at PTC Therapeutics is Dr. Allan Steven Jacobson Ph.D., Co-Founder, Chairman of Scientific Advisory Board & Independent Director, who is 78 years old. Learn More on Pierre Gravier's age.
How do I contact Pierre Gravier?: The corporate mailing address for Mr. Gravier and other PTC Therapeutics executives is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. PTC Therapeutics can also be reached via phone at (908) 222-7000 and via email at [email protected]. Learn More on Pierre Gravier's contact information.
Has Pierre Gravier been buying or selling shares of PTC Therapeutics?: Pierre Gravier has not been actively trading shares of PTC Therapeutics over the course of the past ninety days. Most recently, Pierre Gravier sold 2,269 shares of the business's stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $34.02, for a transaction totalling $77,191.38. Following the completion of the sale, the chief financial officer now directly owns 53,531 shares of the company's stock, valued at $1,821,124.62. Learn More on Pierre Gravier's trading history.
Who are PTC Therapeutics' active insiders?: PTC Therapeutics' insider roster includes Neil Almstead (Insider), Mark Boulding (VP), Pierre Gravier (CFO), Emily Hill (CFO), Allan Jacobson (Director), Matthew Klein (COO), Stephanie Okey (Director), Eric Pauwels (Insider), Stuart Peltz (CEO), Emma Reeve (Director), Michael Schmertzler (Director), David Southwell (Director), Dawn Svoronos (Director), Christine Utter (CAO), Alethia Young (Chief Financial Officer, Bicycle Therapeutics), and Jerome Zeldis (Director). Learn More on PTC Therapeutics' active insiders.
Are insiders buying or selling shares of PTC Therapeutics?: During the last twelve months, PTC Therapeutics insiders bought shares 1 times. They purchased a total of 7,700 shares worth more than $198,737.00. During the last twelve months, insiders at the biopharmaceutical company sold shares 16 times. They sold a total of 56,906 shares worth more than $1,787,917.16. The most recent insider tranaction occured on July, 16th when CFO Pierre Gravier sold 2,269 shares worth more than $77,191.38. Insiders at PTC Therapeutics own 5.5% of the company. Learn More about insider trades at PTC Therapeutics.
Information on this page was last updated on 7/16/2024.

Pierre Gravier Insider Trading History at PTC Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/16/2024	Sell	2,269	$34.02	$77,191.38	53,531
12/12/2023	Buy	7,700	$25.81	$198,737.00	33,700

Pierre Gravier Buying and Selling Activity at PTC Therapeutics

PTC Therapeutics Company Overview

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Today's Range

Now: $52.07

$49.19

$52.97

50 Day Range

MA: $40.52

$34.99

$52.07

2 Week Range

Now: $52.07

$23.58

$52.97

Volume

3,542,300 shs

Average Volume

725,012 shs

Market Capitalization

$4.02 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.63

This company will win the AI race

From Porter & Company | Ad